Literature DB >> 19540820

Leukocytapheresis in ulcerative colitis: a possible alternative to biological therapy?

K O Arseneau1, F Cominelli.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19540820      PMCID： PMC3572230          DOI： 10.1016/j.dld.2009.05.014

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN： 1590-8658            Impact factor:   4.088


× No keyword cloud information.
  6 in total

1.  A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis.

Authors:  Bruce E Sands; William J Sandborn; Brian Feagan; Robert Löfberg; Toshifumi Hibi; Tao Wang; Lisa-Marie Gustofson; Cindy J Wong; Margaret K Vandervoort; Stephen Hanauer
Journal:  Gastroenterology       Date:  2008-04-25       Impact factor: 22.682

Review 2.  The relationship between infliximab treatment and lymphoma in Crohn's disease.

Authors:  S J Bickston; G R Lichtenstein; K O Arseneau; R B Cohen; F Cominelli
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

3.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

4.  Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis.

Authors:  M A de Bièvre; A A Vrij; E J Schoon; G Dijkstra; A E de Jong; A H Oberndorff-Klein Woolthuis; H C Hemker; R W Stockbrügger
Journal:  Inflamm Bowel Dis       Date:  2007-06       Impact factor: 5.325

5.  Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis.

Authors:  S Bloom; S Kiilerich; M R Lassen; A Forbes; K Leiper; E Langholz; E J Irvine; C O'Morain; D Lowson; S Orm
Journal:  Aliment Pharmacol Ther       Date:  2004-04-15       Impact factor: 8.171

Review 6.  Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.

Authors:  N Chande; J W McDonald; J K Macdonald
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16
  6 in total
  5 in total

Review 1.  Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes.

Authors:  Giovanni Tomasello; Pietro Tralongo; Provvidenza Damiani; Emanuele Sinagra; Benedetto Di Trapani; Marie Noelle Zeenny; Inaya Hajj Hussein; Abdo Jurjus; Angelo Leone
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

2.  Successful treatment of ulcerative colitis complicated by Sweet's syndrome by corticosteroid therapy and leukocytapheresis.

Authors:  Tomohiro Terai; Mitsushige Sugimoto; Satoshi Osawa; Ken Sugimoto; Takahisa Furuta; Shigeru Kanaoka; Mutsuhiro Ikuma
Journal:  Clin J Gastroenterol       Date:  2011-03-29

3.  Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease.

Authors:  C B Larmonier; M T Midura-Kiela; R Ramalingam; D Laubitz; N Janikashvili; N Larmonier; F K Ghishan; P R Kiela
Journal:  Inflamm Bowel Dis       Date:  2011-02       Impact factor: 5.325

Review 4.  Gut microbiota imbalance and chaperoning system malfunction are central to ulcerative colitis pathogenesis and can be counteracted with specifically designed probiotics: a working hypothesis.

Authors:  Maurizio Bellavia; Giovanni Tomasello; Marcello Romeo; Provvidenza Damiani; Attilio I Lo Monte; Luciano Lozio; Claudia Campanella; Antonella Marino Gammazza; Francesca Rappa; Giovanni Zummo; Massimo Cocchi; Everly Conway de Macario; Alberto J L Macario; Francesco Cappello
Journal:  Med Microbiol Immunol       Date:  2013-07-18       Impact factor: 3.402

Review 5.  Investigational new drugs in the treatment of inflammatory bowel disease: a review.

Authors:  Imogen Williams; Jason Goh
Journal:  J Exp Pharmacol       Date:  2011-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.